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Introduction 
 
Peripheral artery disease (PAD) is a major cause of morbidity and mortality and is caused by 
the accumulation of atherosclerotic plaques within the lower limb arteries. Critical limb 
ischaemia (CLI) results from progression of this disease leading to chronic muscle ischaemia 
with tissue inflammation, necrosis and apoptosis.(1) Patients with CLI present with rest pain 
with or without ulcers or gangrene. At this stage limb salvage requires surgical or 
endovascular attempts to improve blood flow, however in some patients revascularisation is 
not possible. An increasing number of studies show that even successful revascularisation 
does not always lead to improvements in symptoms, functional status or quality of life.(2, 3) 
Indeed 34% of patients with CLI undergo major limb amputation within 12 months.(4) The 
lack of improvement in symptoms in patients despite revascularisation is due in part to a 
myopathy (5-8) within the ischaemic muscle. The pathophysiology of skeletal muscle 
damage following ischaemia is unclear but a number of detrimental physiological and 
biochemical changes have been identified. However the mechanism of how 
hypoxia/ischaemia activates the damaging pathways in muscle are yet to be elucidated. 
Toll-Like receptors (TLRs) are pathogen recognition receptors (PRR) of the innate immune 
system. They are type 1 membrane glycoproteins that contain an external ligand-binding 
leucine-rich repeat (LRR) motif and a cytoplasmic signalling domain that is similar to the 
Interleukin-1 (IL-1) receptor and thus termed the Toll/IL-1 receptor (TIR) domain. So far 11 
TLRs (TLR 1-11) are thought to be functional in humans and despite their documented role 
in innate immunity they are widely expressed by both immune and non-immune cells 
including skeletal muscle (9). TLRs recognise and are activated by pathogen associated 
molecular patterns (PAMPs) which are microbial molecules that alert the host cell of the 
presence of invading organisms such as bacteria and viruses. In addition to PAMPs, TLRs are 
also stimulated by host derived molecules (10) that are released during tissue injury. 
Endogenous ligands such as high mobility group box 1 protein (HMGB-1) (11), heat shock 
 
 
proteins (HSPs) and hyaluronan (12) have been implicated in ischaemia-induced organ 
damage. 
 
Ligand binding by PAMPs or endogenous molecules leads to TLR dimerization which 
contributes to ligand specificity. All TLRs form homodimers except TLR1, 2 and 6: TLR2 can 
heterodimerise with TLR1 or 6 (13) depending on the stimulating ligand.  Exogenous or 
endogenous ligand stimulation of the TLR signalling pathways, of which there are two 
distinct types, leads to activation of transcription factors such as nuclear factor κB (NF-κB), 
activator protein 1 (AP-1) and the interferon regulatory factors. This in turn leads to 
upregulation of pro-inflammatory cytokines such as tumour necrosis factor α (TNF-α), 
interleukins 1 and 6 (IL-1 & 6) and type 1 interferons (IFN). Further, TLR activation has been 
reported to directly cause apoptosis via Fas-associated death domain protein (FADD) and 
caspase 8 (14). 
Signal transduction following TLR stimulation is dependent upon the TIR domain binding to 
an adapter protein. There are four adapter proteins that are involved: myeloid 
differentiation primary response protein 88 (MyD88), TIR domain-containing adapter 
protein (TIRAP/Mal), TIR domain-containing adapter inducing IFNβ (TRIF) and TRIF-related 
adapter molecule (TRAM) (15). The two distinct TLR signalling pathways are the MyD88 
dependent and the MyD88 independent pathways whose main adapter proteins are MyD88 
and TRIF respectively. All TLRs signal via the MyD88 dependent pathway apart from TLR3 
which signals via the MyD88 independent pathway, whilst TLR 4 can signal via either 
signalling mechanism. The subsequent propagation of the signalling pathway involves the 
interleukin-1 receptor associated kinase (IRAK) and MAP kinase family. In the TLR signalling 
pathway the quiescent NF-κB is sequestered by the inhibitor of NF-κB (IκB) protein. 
Following TLR stimulation and signal transduction, IκB protein is phosphorylated and 
polyubiquitylated which releases NF-κB to translocate to the nucleus and activate gene 
transcription. 
There is emerging evidence suggesting that TLRs play an important role in ischaemia and 
ischaemia/reperfusion induced tissue damage in the kidneys, liver, central nervous and 
cardiovascular systems (16). In particular TLR2 and 4 activation has been strongly associated 
with ischaemia-induced organ damage (17, 18). TLR2 and 4 knockout mice have been shown 
to be protected against ischaemia-induced liver (19), renal (20) and myocardial (21) injury. 
Further studies have shown that this protective effect is associated with a reduction in pro-
inflammatory cytokine expression (22) and NF-κB nuclear translocation (21). Despite this 
strong association between TLRs and ischaemia-induced pathogenesis, very little work has 
focused on the role that TLRs play in skeletal muscle damage in CLI.  
Current treatments for CLI are aimed at improving blood flow.  However there is significant 
evidence to suggest that this does not always help improve patient symptoms. We have 
 
 
therefore taken a novel approach of studying the affected end organ, i.e. the skeletal 
muscle itself in order to understand whether TLR2 and TLR6 play a role in the ischaemia-
induced muscle damage. A better understanding of this pathological process may identify 
potential therapeutic targets that may be used in conjunction with revascularisation. 
 
 
Methods 
 
Human gastrocnemius muscle biopsy 
Open gastrocnemius muscle biopsies were obtained from patients undergoing perigenicular 
amputation for CLI and non-ischaemic control samples were obtained from patients 
undergoing great saphenous vein harvesting for coronary artery bypass grafting. Twelve 
patients from each group were biopsied. The biopsy is taken as an excisional biopsy rather 
than using a biopsy needle. Thus the sample size of the biopsy is approximately 4mm by 
4mm. At least 3 biopsies were taken from the patient with PAD whilst 1 sample per patient 
was taken from the control patients. The sample is taken from the medial head of the 
gastrocnemius muscle and any areas with macroscopic necrosis were avoided.  To ensure 
that none of the control patients had flow limiting PAD, all patients with an ankle-brachial 
pressure index (ABPI) of <0.9 were excluded from the control group. In addition any patient 
with an infected ulcer or trauma were also excluded from the sample collection. There was 
no significant difference in the age related risk factors between the 2 groups (Figure 1a). We 
have previously shown that hypoxia-inducible factor 1α a marker of hypoxia is elevated in 
muscle samples from patients with CLI compared to control (23). The same technique was 
used to harvest the muscle samples in both groups and the tissue was snap frozen in liquid 
nitrogen and stored at -80°C until use.  
 
Cell cultures  
 The C2C12 mouse myoblast cell line (European Collection of Cell Cultures (ECACC) no. 
91031101, passage no. 13, Salisbury, UK) was plated onto 12-well culture plates (BD 
Falcon™, cat. no. 351143, Flintshire, UK) or 8-well chamber slides (BD Falcon, cat. No. 
354108, Flintshire, UK) and cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, 
Paisley, Scotland) supplemented with 10% fetal calf serum, penicillin (100U/mL), 
streptomycin (100 µg/mL) and amphotericin B (25 µg/mL, all from Gibco). At 80% 
confluence, cells were switched to differentiation medium containing DMEM with 2% horse 
serum penicillin (100U/mL), streptomycin (100 µg/mL) and amphotericin B (25 µg/mL, all 
from Gibco). Differentiation was confirmed by changes in morphology (supplementary 
 
 
Figure 1) as well changes in the expression of myogenin protein. Myogenin is preferentially 
expressed in skeletal myotubes but not myoblasts (23). Following differentiation, usually at 
day 7-8, myotubes were exposed to simulated ischaemia or normoxia with or without 
relevant pre-treatments.  
 
 
Simulated ischaemia 
 
We have developed a model of simulated ischaemia that has previously been described 
(23). Chronic ischaemia is difficult to replicate in vitro, however the aim of the simulated 
ischaemia model was to create an in vitro environment that matched the parameters of 
chronic ischaemia such as PO2, CO2, pH, apoptosis and lactate dehydrogenase release which 
have been demonstrated in skeletal muscle of patients with CLI. Briefly, 24 hours following 
culture media change, myotubes (in open dishes) were exposed to 20% CO2+80% N2 
(British Oxygen, Luton, UK) in hypoxic chambers (Modular Incubator Chamber, MIC-101; 
Billups-Rothenberg, Del Mar, CA, USA). The chamber was flushed with gas at 10 l/min for 
20 min and then sealed. The apparatus was placed in an incubator at 37°C for 8, 24 and 72h. 
Control myotubes were maintained under normoxic conditions (21% O2+5% CO2) for 8h. 
The oxygen tension of the ischaemic media was 6.8kPa compared to 16.2 kPa in control 
media. The media was collected and centrifuged at 1600 g for 5 min at 4°C and stored at 
−20°C. The myotube monolayer was harvested on ice, washed with cold PBS and following 
this, 75 μl RIPA buffer 1 × solution (150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium 
deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8.0; product number R0278; Sigma Aldrich, St 
Louis, MO, USA) and 75 μl of Laemmli buffer was added to each well. The monolayer was 
scrapped with a cell scrapper and collected into a 1.5 mL Eppendorf tube using a syringe 
with a 23 G needle. A total of 5 μl (2–5%) of 2-mercaptoethanol was added to the cell 
extract, which was then heated at 95°C for 5 min. Extracts were then centrifuged at 1600 g 
for 5 min at 4°C. The supernatant was collected and stored at −80°C for western blot 
analysis. 
  
Pre-treatment studies  
 To investigate the role of TLR2 and TLR6 and the downstream signalling pathways involved 
in ischaemia-induced apoptosis and IL-6 induction, the following agonist and neutralising 
antibodies/inhibitors were used: TLR2/6 agonist PAM2CSK4 (10μg/mL; EMC-
MicroCollections, Tuebingen, Germany) was incubated with myotubes for 8h; anti-TLR2 
antibody (50μg/mL; T2.5; eBioscience, San Diego, USA) and anti-TLR6 antibody (1.25μg/mL; 
pab-hstlr6;  Invivogen, San Diego, USA) was added to the myotubes 30mins prior to 
incubating in ischaemia or added with PAM2CSK4; MyD88 inhibitor (100μg/mL; tlrl-pimyd; 
Invivogen) was added 24h prior to incubating in ischaemia;  TRIF inhibitor (20μM; tlrl-pitrif; 
 
 
Invivogen) was added 6h prior to incubating in ischaemia; and NF-κB inhibitor (10μM; 
Celastrol ant-cls; Invivogen) was added just before incubating in ischaemia (all based on 
dose-ranging experiments; data not shown).  
  
Immunocytochemistry  
  
TLR2 and TLR6 co-localisation  
 OCT embedded gastrocnemius muscle was cut into 6μm sections and mounted for double-
immunofluorescence staining. Sections were fixed with ice cold acetone and blocked with 
10% chicken serum. Following this, sections were incubated in rabbit anti-human TLR2 
antibody (1:50, sc-10739; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and goat anti-
human TLR6 antibody (1:50, sc-5657; Santa Cruz Biotechnology). After incubation with 
primary antibody or its IgG isotype control for 1h at room temperature, slides were washed 
with PBS and treated with Texas Redchicken Anti-Rabbit (1:200, Invitrogen) and FITC-
chicken Anti-goat (1:200, Invitrogen) secondary antibodies. The slides were washed with 
PBS and coverslips were mounted using VECTASHIELD® mounting medium containing DAPI. 
The images were viewed using a fluorescence microscope (Axioscop 2; Carl Zeiss Micro-
imaging).   
  
Apoptosis  
 Cleaved caspase-3 expression was used to assess apoptosis. Chamber slides were removed 
from the hypoxic chamber and the myotube monolayer was fixed in 4% formaldehyde for 
5 min. Serum block was performed with 10% goat serum and cells were incubated with 
Cleaved caspase-3 (Asp175) antibody (1:50 Cell Signalling Technology, Danvers, MA, USA) or 
its IgG isotype control for 1h at room temperature. Slides were then treated with Texas 
Red®-X goat anti-mouse IgG antibody (Invitrogen), in 1:1000 dilution for 60 min in the dark 
at room temperature. The slides were washed with PBS and coverslips were mounted using 
VECTASHIELD® mounting medium containing DAPI. The images were viewed using a 
fluorescence microscope.  
  
Western blot analyses  
 Equal amounts of denatured protein were loaded per lane (24μg) and were separated on 
12% Tris-glycine gel followed by transfer onto a nitrocellulose membrane (Hybond-C extra; 
GE Healthcare Life Sciences, Buckinghamshire, UK). The membranes were blocked with 5% 
milk in PBS/0.1% Tween 20 and incubated overnight at 4°C with the following antibodies: 
 
 
TLR2 (1:500; sc-10739; Santa Cruz), TLR6 (1:500; sc5661; Santa Cruz), TLR6 (1:500; ab-71429; 
Abcam, Cambridge, UK),  
NF-κB (1:1000;C22B4; Cell Signalling), Phospho-NF-κB (1:2000; 93H1; Cell Signalling);  
IκBα (1:1000; Cell Signalling); Phospho-IκBα (1:1000; Cell Signalling); cleaved caspase-3  
(1:1000; 9661;Cell Signalling); BAX (1:500; sc-526; Santa Cruz), BCL-2 (1:500; sc-783; Santa 
Cruz), HMGB-1 (1:1000; ab18256; Abcam) and β-tubulin-loading control (1:10000; ab4074; 
Abcam). The membranes were then washed and incubated with horseradish peroxidase-
linked corresponding secondary antibody at room temperature. The membrane was 
developed using chemiluminescent substrate (Amersham ECL Plus™ Western Blotting 
Detection Reagent; GE Healthcare Life Sciences) and the blots were developed against 
photographic film (Amersham Hyperfilm ECL, GE Healthcare Life Sciences). Band intensities 
were determined by densitometry using Biospectrum® AC imaging system (UVP, Upland, CA, 
USA).  
  
Immunoprecipitation  
 Ischaemic and control C2C12 myotube monolayers were lysed with lysis buffer (1%SDS, 
1.0mM sodium-orthovandate, 10MM Tris pH 7.4). The lysate was than boiled for 5mins, 
sonicated and centrifuged.  100μl of lysate was incubated at 4oC for 1h with 2μg anti-TLR2 
(sc10739) or anti-TLR6 (sc5661), 400μl H2O and 2X immunoprecipitation buffer (2% Triton X-
100, 300mM NaCL, 20mM Tris pH 7.4, 2mN EDTA, 2mM EGTA pH 8.0, 0.4mM 
sodiumorthovandate, 0.4mM PMSF, 1% NP-40). Subsequently the lysate was incubated with 
50μl protein G-Sepherose (P3296; Sigma-Aldrich, UK) for 30mins at 4oC with agitation. 
Bound proteins were than washed twice with 1X immunoprecipitation buffer and the pellet 
resuspended in 45μl 2X laemlli buffer. Immune complexes were separated by Tris-glycine, 
transferred to nitrocellulose, and immunoblotted with TLR2 or TLR6 antibodies. Following 
optimisation of the antibody and technique for the immunoprecipitation studies we did not 
include IgG control for further experiments. Proteins were visualized by using 
chemiluminescence followed by exposure to photographic film. 
 
 
IL-6 Assay 
IL-6 protein concentrations in the culture media were determined using an ELISA kit (Mouse 
IL-6 ELISA Ready-SET-Go!®; eBioscience, San Diego, USA) following the manufacturer’s 
protocol. Samples and known standards were assayed in triplicate. The lower detection limit 
was 4pg/mL. 
 
 
 
Statistical Analysis 
Data was analysed with GraphPad Prism software, version 5.  Parametric data were 
compared using a 2-tailed Student’s T-test and Analysis Of Variance (ANOVA)/Turkey HSD 
test, values represent mean±SE.  Non-parametric data were described using median± range 
and were compared using a 2-tailed Mann-Whitney U test.  P-value <0.05 was considered 
statistically significant. 
Informed Consent Statement 
All procedures followed were in accordance with the ethical standards of the responsible 
committee on human experimentation (institutional and national) and with the Helsinki 
Declaration of 1975, as revised in 2000. Written informed consent was obtained from 
patients with prior approval from the Royal Free & Medical School Research Ethics 
Committee (REC Ref: 29-2000). 
No animal studies were carried out by the authors for this article 
 
 
Results 
TLR2 and TLR6 protein expression is upregulated in critically ischaemic muscle and in 
C2C12 myotubes exposed to simulated ischaemia     
TLR1-7 have been shown to be expressed in skeletal muscle (9) and a number of studies 
have demonstrated that their expression is upregulated following ischaemia in various 
organ systems. However previous studies have not looked at the effect skeletal muscle 
ischaemia on TLR expression. We found a significant upregulation of TLR2 (P=0.004) and 6 
(p=0.002) protein expression in muscle from patients with CLI (Figure 1b & d). During our 
optimisation of the in vitro ischaemia model we investigated different durations of hypoxia, 
thus exposing the myotubes to 8h, 24h and 72h. We found that 8h was the optimum 
duration for the myotubes to be exposed to ischaemia in terms of ischaemic parameters 
such as the pH, PO2, CO2 and lactate. Longer periods of exposure to hypoxia began to effect 
the viability of the myotubes. We observed that 8h and 24h ischaemia did not have a 
significant effect on TLR2 and TLR6 expression (Data not shown). However myotubes 
exposed to 72h ischaemia showed a significant upregulation of TLR2 (P= 0.006) and 6 
(P=0.0014) protein expression (Data not shown).                             
   
TLR2 and 6 co-localise and co-immunoprecipitate in muscle following ischaemia with 
subsequent activation of the TLR signalling pathway 
 
 
TLR 2 heterodimerises with TLR1 or 6 depending on the ligand that is presented. We found 
increased TLR2 and TLR6 co-localisation in ischaemic human muscle (Data not shown) as 
well as co-immunoprecipitation of TLR2 and TLR6 following ischaemia (Figure 1f). This would 
suggest that ischaemia leads to TLR2 and TLR6 heterodimerisation and activation of the 
signalling pathway. In its inactive form NF-κB is bound to the inhibitory complex IκBα. 
Following TLR pathway activation, IκBα is phosphorylated and NF-κB is released.  Further, 
optimal NF-κB activation occurs following phosphorylation of the p65 sub-unit of NF-κB. 
Considering these principles we assessed protein expression of IκB and NF-κB (p65) as well 
as their phosphorylated forms in control and ischaemic C2C12 myotubes. Protein expression 
of both IκB (P=0.0028; Figure 2a) and NF-κB (P=0.003; Figure 2c) was reduced in ischaemic 
myotubes. Conversely there was significantly increased expression of the phosphorylated 
form of IκBα (P<0.0001; Figure 2a) and NF-κB (P=0.01; Figure 2c) in ischaemic but not 
control myotubes. This indicated that simulated ischaemia not only leads to TLR2 and TLR6 
heterodimerisation but also activation of the TLR signalling pathway and subsequent NF-κB 
activation by its phosphorylation. 
 
TLR2 and 6 blockade reduces ischaemia-induced apoptosis 
Increased apoptosis has been demonstrated in skeletal muscle of patients with PAD (1). We 
therefore evaluated the effect of ischaemia on myotube apoptosis. We found that 
ischaemia increased apoptosis as shown by increased BCL2-associated X protein (BAX) 
(P=0.005; Figure 3b) and decreased B-cell lymphoma 2 (BCL2) (P=0.002; Figure 3b.) 
expression. This finding was confirmed by increased cleaved caspase-3 expression on 
western blot (Figure 3d) and immunofluorescence (Figure 3a). Further, neutralising anti-
TLR2 (P<0.01; Figure 3d) and anti-TLR6 (P<0.01; Figure 3d) antibodies reduced ischaemia-
induced apoptosis as represented by reduced cleaved caspase-3 protein expression on 
western blot. These findings suggest that ischaemia-induced apoptosis is mediated via TLR2 
and TLR6 activation in skeletal muscle. 
 
Ischaemia-induces skeletal muscle inflammation via TLR2 and TLR6 
Patients with PAD have been reported to have high levels of circulating cytokines such as 
TNF-α and IL-6 (24) and ischaemia itself is known to trigger the release of inflammatory 
cytokines in a variety of organs. We found that IL-6 release was significantly upregulated in 
the media of the ischaemic myotubes (P<0.01; Figure 4a). In addition, the TLR2 and TLR6 
agonist PAM2CSK4 also increased IL-6 (P<0.01; Figure 4a) release in the absence of an 
ischaemic stimuli. Further, neutralising anti-TLR2 (P<0.01) and 6 (P<0.01) antibodies both 
reduced the ischaemia-induced IL-6 release indicating that the IL-6 release was mediated via 
the activation of these 2 receptors (Figure 4a).  
 
 
 
Ischaemia-induced IL-6 generation and apoptosis is mediated via MyD88 signalling 
pathway and NF-κB activation 
 
TLR signal transduction is mediated via the MyD88 dependent and MyD88 independent 
pathways and this leads to the activation of a number of transcription factors such as NF-κB 
and AP-1. We sought to determine whether both pathways are utilised in ischaemia-induced 
apoptosis and IL-6 release and whether IL-6 generation is a result of NF-κB activation.  
C2C12 myotubes were pre-treated with a MyD88, TRIF or NF-κB inhibitor prior to exposure 
to 8h simulated ischaemia. The C2C12 myotubes pre-treated with the MyD88 (P<0.01) and 
NF-κB (P<0.01) inhibitors showed reduced IL-6 generation, whilst TRIF inhibition as well the 
MyD88 and TRIF control peptides did not reduce ischaemia-induced IL-6 release (Figure 4b). 
Further MyD88 inhibition but not TRIF inhibition reduced ischaemia-induced apoptosis as 
shown by the reduced cleaved caspase-3 expression (Figure 5a). My88 inhibition disrupted 
ischaemia-induced NF-κB phosphorylation and hence activation however TRIF inhibition did 
not abrogate ischaemia-induced NF-κB activation (Figure 5c). 
 
Potential Endogenous Ligands 
Among the endogenous ligands or damaged associated molecular patterns (DAMPs) that 
activate TLRs, HMGB-1 and the HSPs have been implicated in activating TLRs following an 
ischaemic insult. We therefore determined the expression of HMGB-1 and HSPs 60(25) and 
70(26) in ischaemic C2C12 myotubes. We have found that following an ischaemic insult 
there was an increase in the expression of HMGB-1 (P=0.007; Figure 6a), HSPs 60 (P=0.0003; 
Figure 6c) and 70 (P<0.0001; Figure 6c) 
 
Discussion 
The management of CLI is pre-dominantly aimed at improving blood flow or in severe cases 
major amputation is required to prevent progression of gangrene. However despite 
successful improvement in blood flow to the ischaemic leg many patients still complain of 
no improvement of symptoms in terms of pain, exercise tolerance and quality of life and 
therefore deem the surgery to be unsuccessful. The exact pathophysiology as to why these 
patients have ongoing muscle dysfunction despite the restoration of blood flow is unclear. 
However emerging evidence suggests that this may be due to ischaemia-induced skeletal 
muscle damage and it is thought that inflammation plays a central role in this process (27). 
In support of the theory that inflammation plays an important role in skeletal muscle 
damage in CLI, it has been shown that raised levels of circulating pro-inflammatory 
cytokines such as TNFα, IL-6 and chemokines are found in patients with PAD (24). 
The discovery of TLRs and their role in immunity and inflammation has led to significant 
advances in terms of understanding the pathophysiology of ischaemia and 
ischaemia/reperfusion mediated organ injury. In particular TLR2 and TLR4 have been 
 
 
strongly implicated in myocardial injury following sustained ischaemia and TLR 2 (28) and 
TLR4 (29) knockout mice have been shown to have reduced myocardial infarct size. These 
emerging studies along with the fact TLRs are also expressed on skeletal muscle provide a 
potential understanding of how ischaemia in CLI patients causes skeletal muscle damage. 
Preliminary studies using focussed RT-PCR microarray studies carried out in our lab 
demonstrated upregulation of gene expression of cell surface TLRs 1, 2, 4 and 6 as well as 
TLR-related cofactors MyD88 and CD14, and downstream targets IL6, IL8, IRAK1 in muscle 
from CLI patients. TLR2 upregulation was particularly marked; further, TLR 2 and 6 
heterodimerisation had been described (30). Therefore we decided to investigate these 2 
TLRs further. In the present study, we have not only shown that TLR2 and TLR6 are 
expressed on human skeletal muscle but that their expression is increased in ischaemic 
skeletal muscle. We observed from immunofluorescence staining that TLRs are expressed 
on endothelium (CD31), neutrophil (CD43), and macrophages (CD68) within muscle tissue.  
Given this wide spread expression as well as known expression of TLRs on muscle cells, we 
decided to focus here on the effect of ischaemia on muscle tissue TLR expression, where the 
TLR activation on individual cell types are likely to exert an autocrine/paracrine effect on the 
tissue as a whole. In order to understand the significance of this finding we have utilised an 
in vitro model of simulated ischaemia previously developed by our group. Significantly TLR2 
and TLR6 expression was upregulated in the ischaemic C2C12 myotubes. These findings 
corroborate with other studies which have shown that ischaemia upregulates TLRs in 
various tissues both in vivo and in vitro. Our experiments have demonstrated that TLR2 and 
TLR6 also heterodimerise under ischaemic conditions suggesting ligand binding and 
activation of the downstream signalling pathway. Indeed we found that IκBα was 
phosphorylated following an ischaemic insult indicating activation of NFκB which is central 
to the translocation of NFκB into the nucleus and the subsequent induction of pro-
inflammatory cytokines. 
Several studies have shown that following ischaemia cellular death results due to apoptosis 
and increased apoptosis of skeletal muscle has also been demonstrated in patients with 
PAD. Our data supports that an ischaemic insult upregulates cellular apoptosis in muscle. 
We have also shown that ischaemia-induced apoptosis in skeletal muscle is reduced by 
neutralising anti-TLR2 and TLR6 antibodies indicating that ischaemia-induced apoptosis is 
mediated via TLR2 and TLR6. The mechanism for this is still poorly understood but studies 
have shown that TLR2 may promote apoptotic cell death via several pathways such as 
activation of the JNK-AP-1 (31) pathway or via a pathway involving Fas-associated death 
domain protein (FADD) and caspase 8 (14).  
IL-6 is a potent inflammatory cytokine that plays a significant role in the pathogenesis of cell 
damage following ischaemia in various tissues. We have established that ischaemia results 
in an increase in IL-6 release by myotubes whilst inhibiting TLR2 and TLR6 reduced IL-6 
production. This would suggest that TLR2 and TLR6 are important in the ischaemia-induced 
 
 
upregulation of IL-6 and any subsequent muscle damage propagated by this inflammatory 
cytokine. 
We further sought to elucidate which TLR signalling pathway is implicated in these 
potentially pathological processes. We found that ischaemia-induced NFκB phosphorylation, 
apoptosis and IL-6 production in skeletal muscle is mediated via the MyD88 dependent and 
not the MyD88 independent (TRIF Dependant pathway). The MyD88 pathway may therefore 
be a potential therapeutic target in reducing ischaemic muscle damage. In addition by 
targeting a specific pathway, potential side effects of any medical therapy would be kept to 
a minimum. 
Several TLR2 and TLR6 endogenous ligands have been identified that are released in 
response to stress. In particular HMGB-1, HSPs 60 and 70 have already been implicated in 
the pathogenesis of renal, liver and myocardial damage following ischaemia. We have 
shown in our previous studies that there is upregulation in the expression of HMGB-1, HSPs 
60 and 70 following ischaemia; further HMGB-1 and HSP 60 have been shown to co-localise 
with TLR2 and TLR4 (32, 33). Therefore, one can speculate that these endogenous ligands 
may be activating TLR2 and TLR6 and propagating the skeletal muscle damage in patients 
with limb ischaemia. However, we have yet to identify whether these potential endogenous 
ligands specifically activate TLR 2 and TLR 6 following skeletal muscle ischaemia or whether 
there is an alternative mechanism for their activation. Recombinant HMGB-1 has been 
shown to worsen myocardial injury following I/R whereas treatment with the HMGB-1 
antagonist HMGB-1 box A reduced infarct size (11). Thus, it would be interesting to see 
whether antagonising HMGB-1, HSPs 60 or 70 may reduce skeletal muscle damage following 
an ischaemic insult.  
This study has several limitations: analyses of our muscle biopsies from patients provided 
only observational evidence for the involvement of TLR2 and TLR6 in ischaemic skeletal 
muscle. Further investigation was carried out in an in vitro model where C2C12 myotubes 
were used. This is an established murine cell line which may not fully reflect the situation in 
human cells. In vitro models are also not representative of the complex in vivo conditions 
that occur. However, using a combination of patient tissue analyses and in vitro experiments 
has allowed us to start elucidating potential pathways for more detailed investigation. As 
previously mentioned other TLRs have shown to play a role in ischaemia induced damage 
(34). In particular TLR 2 has also been shown to heterodimerise with TLR1 under certain 
conditions. It would not be surprising that the other TLRs may be also be playing a role in 
skeletal muscle injury as the functional 11 TLRs mediate their signalling via the same 
pathways. Therefore it should be pointed out that whilst we have shown that TLR2 and TLR6 
play role in ischaemia induced skeletal muscle damage future studies focusing on the other 
TLRs in particular TLR4 would be beneficial. 
In conclusion we have shown that TLR2 and TLR6 are upregulated in skeletal muscle 
following ischaemia. The receptors heterodimerise leading to activation of the MyD88 
 
 
signalling pathway with subsequent activation of NFκB. This results in upregulation of the 
inflammatory cytokine IL-6 as well as increase in muscle apoptosis. It is most likely that this 
results in an environment whereby the inflammatory milieu leads to a myopathy and thus 
limits the therapeutic effect of revascularisation. Our study has therefore identified 
potential therapeutic targets such as the MyD88 signalling pathway which may be blocked 
in order to prevent or reduce muscle damage. It is possible that medical therapy with the 
aim of reducing the skeletal muscle damage in conjunction with improvement in blood flow 
may provide symptomatic relief and improve functional outcomes. 
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Figure Legends 
Figure 1 
(a) Table demonstrating patient characteristics including risk factors for atherosclerotic 
vascular disease. (b & d) Representative TLR2 and 6 western blots of control and CLI patient 
muscle samples.  Blot was reprobed for β-Tubulin expression as control for protein loading. 
(c & e) Densitometric quantification of TLR 2 and 6 levels in CLI muscle, values are median 
and range, *p<0.01 compared to control, Mann-Whitney U Test, n=12.  (f) TLR2 
heterodimerises with TLR6 following ischaemia.  
 
Figure 2 
(a) Representative western blot showing downregulation of IκBα and upregulation of P- IκBα 
in C2C12 myotubes exposed to 8h of simulated ischaemia compared to control myotubes. 
Protein loading was consistent as shown by β-Tubulin levels.  (b) Densitometric analyses of 
western blots, values are means ± standard error (SE), n = 3, *p<0.05 unpaired t-Test(c) 
Representative western blot showing downregulation of NF-κB and upregulation of P-NF-κB 
in C2C12 myotubes exposed to 8h of simulated ischaemia compared to control myotubes. 
Protein loading was consistent as shown by β-Tubulin levels.  (d) Densitometric analyses of 
western blots, values are means ± SE, n = 3, *p<0.05 unpaired t-Test. 
 
Figure 3  
(a) Immunofluorescence staining for DAPI (blue) and cleaved caspase-3(green) was 
performed on control and ischaemic myotubes as well ischaemic myotubes incubated with 
neutralising anti-TLR2 antibody. There is increased cleaved caspase-3 staining in the 
ischaemic myotubes and significantly reduced cleaved caspase-3 staining in the ischaemic 
myotubes with anti-TLR2 antibody. (b) Representative western blot showing 
downregulation of BCL2 and upregulation of BAX in C2C12 myotubes exposed to 72h of 
simulated ischaemia compared to control myotubes. Protein loading was consistent as 
shown by β-Tubulin levels.  (c) Densitometric analyses of western blot, values are means ± 
SE, n = 9. *p<0.05 unpaired t-Test. (d) Representative western blot showing increased 
cleaved caspase-3 expression following 8h simulated ischaemia. Protein loading was 
consistent as shown by β-Tubulin levels.  (e) Densitometric analyses of western blots, values 
are means ± SE, n = 3. P<0.0001, ANOVA, *, denotes ischaemic myotubes; **, denotes Anti-
TLR2 or 6 Antibody + ischaemic myotubes. Turkey HSD test, P <0.01 between: * and control 
myotubes; * and ** myotubes. 
 
 
 
Figure 4 
(a) IL-6 generation in C2C12 myotube supernatant was measured by ELISA. Myotubes were 
exposed to simulated ischaemia for 8h with or without anti-TLR2 or 6 antibodies. Values are 
mean ± SE, n = 9.  P<0.0001, ANOVA. Turkey HSD test: * P <0.01 vs control, **P<0.01 vs 
control, †P<0.01 vs ischaemia, ††P<0.01 vs ischaemia. (b) IL-6 generation in C2C12 myotube 
supernatant was measured by ELISA. Myotubes were pre-treated with specific inhibitors or 
control peptides and exposed to simulated ischaemia for 8h. Values are mean ± SE, n= 9.  
P<0.0001, ANOVA. Turkey HSD test: * P <0.01 vs control, **P<0.01 vs ischaemia, †P<0.01 vs 
ischaemia. 
 
Figure 5 
(a) Representative western blot showing decreased Cleaved Caspase-3 expression. MyD88 
inhibition significantly reduced ischaemia-induced Cleaved caspase-3 expression.  Protein 
loading was consistent as shown by β-Tubulin levels.  (b) Densitometric analyses of western 
blots, values are means ± SE, n = 9. P<0.0001, ANOVA. Turkey HSD test:* P <0.01 vs control, 
** P<0.05 vs Ischaemia. (c)  Representative western blot showing NF-κB and P- NF-κB 
expression in C2C12 myotubes exposed to 8h of simulated ischaemia. Protein loading was 
consistent as shown by β-Tubulin levels.  (d) Densitometric analyses of western blots, values 
are means ± SE, n = 6. P<0.0001, ANOVA. Turkey HSD test: NF-κB expression; * P <0.01 vs 
control, ** P<0.01 vs Ischaemia, P-NF-κB expression; * P <0.05 vs control, ** P<0.01 vs 
Ischaemia. 
 
Figure 6 
(a) Representative western blot showing upregulation of HMGB-1 in C2C12 myotubes 
exposed to 8h of simulated ischaemia compared to control myotubes. Protein loading was 
consistent as shown by β-Tubulin levels. (b) Densitometric analyses of western blots, values 
are means ± SE, n = 6. *p<0.05 unpaired t-Test. (c) Representative western blot showing 
upregulation of HSPs 60 and 70 in C2C12 myotubes exposed to 8h of simulated ischaemia 
compared to control myotubes. Protein loading was consistent as shown by β-Tubulin 
levels. (d) Densitometric analyses of western blots, values are means ± SE, n = 6. *p<0.05 
unpaired t-Test. 
Supplementary Figure  
Hematoxylin and eosin (H&E) staining confirming differentiation of C2C12 myoblasts (a) into 
multinucleated myotubes (b). 
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